Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma

Journal of Experimental Medicine

Volumn 168, Issue 6, 1988, Pages 2183-2191

  Kawakami, Yutaka ^a   Rosenberg, Steven A ^a   Lotze, Michael T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

CANCER IMMUNOTHERAPY; CELL CULTURE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL;

CELLS, CULTURED; HUMAN; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKINS; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0024210868     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.168.6.2183     Document Type: Article

References (18)

1. Rosenberg, S. A., M. T. Lotze, L. M. Muul, A. E. Chang, F. R Avis, S. Leitman, W. M. Linehan, C. N. Robertson, R. E. Lee, J. T. Rubin, C. A. Seipp, C. G. Simpson, and D. E. White. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316:889.
2. Muul, L. M., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138:989.
3. Topalian, S. L., L. M. Muul, D. Solomon, and S. A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods. 102:127.
4. Topalian, S. L., D. Solomon, E P. Avis, A. E. Chang, W. M. Linehan, M. T. Lotze, C. N. Robertson, C. A. Seipp, P. Simon, C. G. Simpson, and S. A. Rosenberg. 1988. Therapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839.
5. Lotze, M. T., S. Tomita, and S. A. Rosenberg. 1988. Human tumor antigens defined by cytotoxic and proliferative T cells. In Human Tumor Antigens and Specific Tumor Therapy. R. Metzgar and M. Mitchell, editors. Alan R. Liss, Inc., New York. In press.
6. Fisher, B., B. Packard, J. Carrasquillo, E. J. Read, C. S. Carter, S. Topalian, J. Yang, P. Yolles, S. Larson, andS. A. Rosenberg. 1988. Traffic of tumor infiltrating lymphocytes (TIL) to metastatic tumor deposits: human studies. Proc. Am. Soc. Clin. Oncol. Annu. Meet. 247. (Abstr.).
7. Paul, W. E., and J. Ohara. 1987. B-cell stimulatory factor-l/interleukin 4. Annu. Rev. Immunol. 5:429.
8. Yokota, T, N. Arai, J. De Vries, H. Spits, J. Banchereau, A. Zlotnik, D. Rennick, M. Howard, Y. Takeba, S. Miyatake, F. Lee, and K. Arai. 1988. Molecular biology of inter-leukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells, and hemopoietic cells. Immunol. Rev. 102:137.
9. Spits, H., H. Yssel, Y. Takebe, N. Arai, T. Yokota, F. Lee, K. Arai, J. Banchereau, and J. E. De Vries. 1987. Recombinant interleukin 4 promotes the growth of human T cells. J. Immunol. 139:1142.
10. Kawakami, Y., M. Custer, S. A. Rosenberg, and M. T. Lotze. 1988. Human interleukin 4 (IL4) inhibits interleukin 2 (IL2) induction of human lymphokine activated killer (LAK) activity from peripheral blood and spleen cells. FASEB(Fed. Am. Soc. Exp. Biol.)J. 2:A660. (Abstr.).
11. Widmer, M. B., R. B. Acres, H. M. Sassenfeld, and K. H. Grabstein. 1987. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J. Exp. Med. 166:1447.
12. Spits, H., H. Yssel, X. Paliard, R. Kastelein, C. Figdor, and J. de Vries. 1988. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J. Immunol. 141:29.
13. Lotze, M. T., E. Grimm, A. Mazumder, J. L. Strausser, and S. A. Rosenberg. 1981. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res. 41:4420.
14. Mule, J. J., C. A. Smith, and S. A. Rosenberg. 1987. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J. Exp. Med. 166:792.
15. Rosenberg, S. A., P. Speiss, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (Wash. DC). 233:1318.
16. Ettinghausen, S. E., R. K. Puri, and S. A. Rosenberg. 1988. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant Interleukin-2 in mice. J. Nat. Cancer Inst. 80:177.
17. Kurt-Jones, E. A., S. Hamberg, J. Ohara, W. E. Paul, and A. K. Abbas. 1987. Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness. J. Exp. Med. 166:1774.
18. Ashwell, J. D., R. J*. Robb, and T. R. Malek. 1986. Proliferation of T lymphocytes in response to interleukin 2 varies with their state of activation. J. Immunol. 137:2572.